AIT Therapeutics Reports Financial Results for Three Months Ended

Therapeutics Reports Financial Results for Three Months Ended March 31, 2018

positive top-line data for Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study

data from its inhaled Nitric Oxide study in patients infected with mycobacterium abscessus complex (MABSC) at the 2018 American

Thoracic Society Conference

IP with new patent for the Smart Filter for the nitric oxide generator and delivery system and patent allowance for delivery of

inhaled nitric oxide at concentrations of at least 160ppm for treatment of bronchiolitis in infants

Stephen J. DiPalma as Chief Financial Officer

Call scheduled for Thursday, June 14 at 8:30 a.m. Eastern Time

YORK, June 14, 2018 (GLOBE NEWSWIRE) - AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused

on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections

and pulmonary hypertension, today announced financial results for the fiscal fourth quarter and year ended March 31, 2018.

Fourth Quarter and Recent Corporate Highlights:

are very pleased with the progress the Company has made over the past several months. We have positive top-line data from our

NO-BRO pilot study showing clear improvement in hospital length-of-stay in bronchiolitis patients; we presented positive data

from our NO-NTM study at the 2018 ATS conference; and we strengthened our patent portfolio surrounding our nitric oxide generator

and delivery system and the use of NO in treating bronchiolitis patients," said Mr. Steven Lisi, Chairman and Chief Executive

Officer. "Our team is continuing to execute the strategy which will improve the lives of patients and create value for our

shareholders. We anticipate submitting a 510k application in pulmonary hypertension around calendar year-end 2018; meeting with

the FDA to discuss the potential pivotal trial design in a NO-NTM study; and preparing to initiate a pivotal trial in bronchiolitis

in the fourth quarter of calendar year 2019."

results for three months ended March 31, 2018

Company announced a change in its Company's fiscal year end from December 31 to March 31. The change resulted in a three-month

transition period that began on January 1, 2018 and ended on March 31, 2018. The Company's 2019 fiscal year will commence

on April 1, 2018. As a result of the change, the following financial results reflect the three-month transition period ended March

the three months ended March 31, 2018, the Company posted net income of $1.0 million, or $0.15 per share. The Company had a $3.5

million benefit from the revaluation of warrants to purchase common stock, which is a non-cash item.

and development expenses were $1.6 million for the three months ended March 31, 2018. Expenses during the three month period were

due to costs related to clinical trials.

and administrative expenses were $0.8 million for the three months ended March 31, 2018.

income for the three months ended March 31, 2018 was $3.5 million, primarily due to the revaluation of the warrants to purchase

of March 31, 2018, the Company had cash and short-term deposits of $9.0 million. This cash balance reflects a financing in the

quarter that resulted in gross proceeds of $9.8 million.

Call & Webcast Information

June 14th @ 8:30am Eastern Time

available through June 28th:

oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions. In the airways, NO

is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest

that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against

other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug

majority of hospital admissions of infants with bronchiolitis are caused by respiratory syncytial virus (RSV). RSV is a common

and highly transmissible virus that infects the respiratory tract of most children before their second birthday. While most infants

with RSV present with minor respiratory symptoms, a small percentage develop serious lower airway infections, termed bronchiolitis,

which can become life-threatening. The absence of treatment options for bronchiolitis limits the care of these sick infants to

largely supportive measures. AIT's system is designed to effectively deliver 160 ppm NO, which has been proven to eliminate

bacteria, viruses, fungi and other microbes from the lungs.

infection is a rare and serious condition causing debilitating pulmonary disease associated with increased morbidity and mortality.

NTM is an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current treatment guidelines

suggest a combination of multiple antibiotics delivered continually over one to two years. These complex, expensive and invasive

regimens have a poor record in the treatment of MABSC. AIT's system is designed to effectively deliver 160 ppm NO, which

has been proven to eliminate bacteria, viruses, fungi and other microbes from the lungs and may work against antibiotic resistant

pulmonary hypertension of the newborn (PPHN) is a lethal condition and a secondary to failure of normal circulatory transition

at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased

pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4-6.8/1000

live births) with mortality rate ranging between 4-33%. This syndrome complicates the course of about 10% of infants with

respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator and is approved in dozens

of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (EMO) in term and near-term (>34

weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary

hypertension in conjunction with ventilator support and other appropriate agents.

AIT Therapeutics Inc.

Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases.

The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively

addressed with current standards of care as well as pulmonary hypertension in various settings. AIT Therapeutics is currently

advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous

mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.

press release contains "forward-looking statements." Forward-looking statements include statements about our expectations,

beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects.

You can identify such forward-looking statements by the words "expects," "intends," "plans,"

"projects," "believes," "estimates," "likely," "goal," "assumes,"

"targets" and similar expressions and/or the use of future tense or conditional constructions (such as "will,"

"may," "could," "should" and the like) and by the fact that these statements do not relate

strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities,

trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred,

these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from

any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions

and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could

cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements,

including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable

products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting

intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent

portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities;

our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development

of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition

from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators;

and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these

forward-looking statements, except as required by applicable law.

Lisi, Chief Executive Officer

AIT Therapeutics, Inc.

LifeSci Advisors, LLC

dollars in thousands, except share and per share data

dollars in thousands, except share and per share data

STATEMENTS OF COMPREHENSIVE LOSS

dollars in thousands, except share and per share data

OF CONSOLIDATED CASH FLOWS